All Comments by Hiroshi Mori

  1. The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease.
  2. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.
  3. GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain.
  4. The effects of aging and neurodegeneration on apoptosis-associated DNA fragmentation and the benefits of nicotinamide.
  5. Genetic risk factors in Japanese Alzheimer's disease patients: alpha1-ACT, VLDLR, and ApoE.
  6. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females.
  7. Neuropathological assessment of the lesions of significance in vascular dementia.
  8. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease.
  9. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression.
  10. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo.
  11. Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease.
  12. Immunoreactivity of presenilin-1 and tau in Alzheimer's disease brain.
  13. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.
  14. Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex.
  15. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway.